Why the study?
Does serum glycated albumin level predict the presence of coronary artery disease in patients with type 2 diabetes?
Does serum glycated albumin level predict the presence of coronary artery disease in patients with type 2 diabetes?
Serum glycated albumin levels are significantly elevated in type 2 diabetic patients with coronary artery disease, suggesting its potential value as a predictive biomarker.
Should not yet change CAD screening in diabetes; hypothesis-generating for glycated albumin as predictive biomarker.
Coronary artery disease (CAD) is a major vascular complication of diabetes mellitus and reveals high mortality. Up to 30 % of diabetic patients with myocardial ischemia remain asymptomatic and are associated with worse prognosis compared to non-diabetic counterpart, which warrants routine screening for CAD in diabetic population. The purpose of this study was to evaluate the clinical value of serum glycated albumin level in predicting the presence of CAD in patients with type 2 diabetes. Ninety patients with type 2 diabetes were divided into four groups having the coronary artery disease with lumen diameter narrowing < 30 %, Group II with mild CAD contained those patients with lumen diameter narrowing 30-50 %, and Group III with Major CAD contained those subjects with lumen diameter narrowing 50-70 %. Finally group IV with severe CAD including the patients with lumen diameter narrowing > 70 %. Serum levels of glycated albumin was determined using ELISA as well as serum concentrations of glucose, lipids, were taken in questionnaire in all groups. Serum glycated albumin levels were significantly increased in diabetic patients with CAD.
No takes yet. Share an insight, caveat, or question.
Irshad et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: